D.C. Circuit Denies Stay of DOJ Order Moving Medical and FDA-Approved Marijuana to Schedule III
A three-judge panel ruled on September 9, 2026 that challengers had not met the legal test for a stay, so the April 28 order stays in effect while the underlying case continues.
The Case That Isn't About Marijuana's Safety
A federal appeals court just refused to pause a Justice Department order that moved some marijuana out of the government's strictest drug category. That sounds like a ruling on whether marijuana belongs there. It isn't.
On September 9, 2026, a three-judge panel of the U.S. Court of Appeals for the D.C. Circuit denied a motion to freeze the order while the underlying lawsuit plays out[1][2]. The panel's own words were narrow: petitioners "have not satisfied the stringent requirements for a stay pending court review"[1]. That is a ruling about timing. It says nothing about who wins the actual case, which is still pending before the same court[2].
To win a stay, a challenger has to clear a high bar: show they'll likely win the case, show they'll suffer real harm if the order isn't paused, and show the fairness of pausing it outweighs the cost of not pausing it. The panel said the challengers didn't clear that bar right now[1]. That's different from saying the order is lawful.
What Actually Changed on April 28
The order under challenge covers far less than "marijuana rescheduling" suggests. Two DEA rules, published in the Federal Register on April 28, 2026, moved exactly two things from Schedule I to Schedule III: marijuana inside an FDA-approved drug, and marijuana covered by a state medical marijuana license[6][7]. Recreational marijuana stayed exactly where it was, in Schedule I[9].
The distinction matters because of what each schedule allows. Schedule I substances can't legally be made, sold, or dispensed in the U.S. at all, and research on them faces heavy federal restrictions. Schedule III substances can be made, distributed, and dispensed by anyone with a valid DEA registration[18]. So the government's argument is that Schedule I status was itself the obstacle blocking the research critics say hasn't been done yet.
Todd Blanche, who signed the orders as Acting Attorney General, said the change would "enable more targeted, rigorous research into marijuana's safety and efficacy, expanding patients' access to treatments and empowering doctors to make better-informed health care decisions"[9]. DOJ has also stressed the order keeps "strict federal controls" in place for recreational use[8]. A separate DEA hearing on rescheduling marijuana more broadly ran from June 29 to July 15, 2026, and still hasn't produced a recommendation[15][16].
Two Companies, One Argument About Who Gets to Sue
The stay motion came from two groups: the National Drug and Alcohol Screening Association (NDASA), which represents workplace drug-testing companies, and MMJ International Holdings, a company developing cannabis-based drugs meant for full FDA approval[3]. Their complaint isn't really about danger. It's about process and fairness.
NDASA's concern is practical. Once federal law recognizes a legal medical category, a positive THC drug test stops being a simple yes-or-no. Someone now has to figure out whether the result came from a federally recognized medical use or from something still prohibited, and that extra review costs money[3]. NDASA and MMJ also argue DEA skipped a required step: publishing the change for public comment before it took effect, the normal process that lets outside groups file objections and evidence before a rule becomes final[3].
MMJ's complaint is about fairness between two paths to market. One path is years of expensive clinical trials through the FDA. The other is a state medical license. MMJ argues the April order gives the state-license path the same Schedule III status as the FDA path, undercutting the investment that full approval is supposed to reward[3]. Both companies also invoke the 1961 UN Single Convention on Narcotic Drugs, a treaty they say limits how far the U.S. can loosen marijuana controls without violating international commitments[3]. DEA has published its own note arguing its reading of the treaty leaves room for exactly this step[24].
The Justice Department's answer sidesteps all of that. It told the court NDASA identified no concrete harm to any specific member, and that MMJ can't claim it's losing business to a competitor because MMJ doesn't have an approved product on the market yet[4][5]. DOJ went further, arguing the two groups have "pocketbook interests" in keeping marijuana restricted that don't "systemically align" with the American public[4][5]. The challengers called that "meritless diversions" from the real legal questions[4]. Getting the case dismissed on that technical ground, called standing, would let DOJ win without a court ever ruling on whether skipping public comment was improper[4].
The Money Question Nobody's Waiting to Resolve
While the lawsuit continues, something concrete has already changed: taxes. A federal tax rule called Section 280E bars any business that sells a Schedule I or Schedule II drug from deducting normal costs, like rent, payroll, and marketing, from its revenue. In several states, that's meant marijuana businesses owing tax on money that exceeded their actual profit[17].
Section 280E doesn't apply to Schedule III, IV, or V substances. So the medical marijuana now covered by the April order can deduct expenses like any other business, starting the day the order took effect rather than waiting for the lawsuit to finish[17]. Treasury and the IRS have already opened a process for issuing guidance on how that works[19]. Every month the order survives creates more of that kind of reliance, the kind a later court loss would have to somehow unwind.
Recreational marijuana operators get none of this relief, since they're still in Schedule I[9]. And banking remains unresolved either way: as long as marijuana is controlled under federal law at any level, banks and payment processors still carry legal risk for serving the industry. Schedule III alone doesn't fix that.
Who's Left Out of the Room
Congressional Republicans and some social conservatives oppose the underlying policy, not just its legal process. Twenty-six House Republicans, led by Rep. Pete Sessions and Freedom Caucus chair Andy Harris, wrote to President Trump on December 18, 2025, urging him to "oppose rescheduling marijuana, a harmful drug that is worsening our nation's addiction crisis"[11][25]. That letter landed the same day Trump signed an executive order directing the Attorney General to speed up rescheduling, so it reflects the party's longstanding position rather than a reaction to the April order or the September ruling[14][25]. CatholicVote's Kelsey Reinhardt made a related point to Fox News Digital: moving marijuana to Schedule III, she said, would "falsely signal that it's safe and medically proven, when it hasn't gone through FDA approval or long-term safety studies"[12]. That's a real tension, since the state-license category by definition covers products that never went through FDA review.
Reform advocates and the cannabis industry see a structural problem on the other side. DEA's broader rescheduling hearing seated seven participants, and all seven opposed rescheduling; the agency turned away NORML and other pro-reform groups[14]. Whatever recommendation eventually comes out of that hearing will be built mostly on evidence from one side of the debate. That's a fact about how the record was assembled, separate from whether the eventual recommendation turns out to be right.
No non-Western or overseas coverage of the September 9 ruling turned up in the reporting reviewed here. That's worth flagging as a gap in what got covered, not proof that nobody abroad is watching. The closest international thread is legal: senators including Mitt Romney, Jim Risch, and Pete Ricketts have pressed DEA directly on whether its approach complies with the 1961 treaty[23].
How the Coverage Split Without Anyone Getting the Facts Wrong
Fox News built its coverage around Republican and religious-conservative opposition to the policy itself, quoting critics at length while giving DOJ's research rationale a single line, and largely skipping the fact that the order only covers two narrow categories[11][12]. Cannabis trade and reform outlets ran the opposite way: Marijuana Moment led a headline with DOJ's "pocketbook interests" jab at the challengers before explaining their argument, and other trade coverage described the ruling with verbs like "rejects" and "block," which cast a procedural denial as a defeat for prohibition rather than a narrow ruling on stay factors[4][5]. CNBC's business-press framing treated the fight mainly as a midterm election story, which is accurate but sidesteps the legal question entirely[21]. None of these outlets misstated the underlying facts. They just chose different facts to put first.
The case itself is still open. The D.C. Circuit hasn't ruled on whether DOJ was required to run a full public-comment process before reclassifying anything, and it hasn't ruled on whether NDASA or MMJ even have the right to raise that question in court[1][2][4]. The DEA's separate hearing on broader rescheduling, the one that could someday reach recreational marijuana, is still sitting with no recommendation, and some estimates put its next steps into late 2026 or 2027[15][16]. Two tracks, still running, neither one finished.
Summary
On September 9, 2026, a three-judge panel of the U.S. Court of Appeals for the D.C. Circuit refused to freeze a Justice Department order that moved some marijuana out of the federal government's most restrictive drug category[1][2]. The panel said the challengers 'have not satisfied the stringent requirements for a stay pending court review'[1]. That is a ruling about timing, not about who wins. The underlying case goes on[2].
The order under challenge is narrower than the phrase 'marijuana rescheduling' suggests. Two DEA final orders, published April 28, 2026, moved just two things from Schedule I to Schedule III: marijuana inside an FDA-approved drug product, and marijuana covered by a qualifying state medical marijuana license[6][7]. Recreational marijuana is still in Schedule I[9]. A separate DEA hearing on broader rescheduling ran from June 29 to July 15, 2026, and no decision has come out of it[15][16].
The two challengers who asked for the freeze are the National Drug and Alcohol Screening Association, a trade group for workplace drug testing, and MMJ International Holdings, a company developing cannabis-based drugs[3]. They say the Justice Department skipped a required public comment step and went further than the 1961 UN Single Convention on Narcotic Drugs allows[3]. NDASA also says employers will face murkier positive THC tests and higher review costs[3]. The Justice Department says both groups have money riding on prohibition and have not shown the concrete injury courts require to sue[4][5].
The sharpest genuine dispute is not whether marijuana is dangerous. It is whether the government may reclassify a drug by immediate order, or must first run a full public-comment rulemaking — and whether these two challengers are legally entitled to raise the question at all[3][4].
The Event
On September 9, 2026, a three-judge panel of the U.S. Court of Appeals for the D.C. Circuit denied a motion to stay the Justice Department's marijuana rescheduling order[1][2]. The motion had been filed by the National Drug and Alcohol Screening Association and MMJ International Holdings[3]. The panel wrote that petitioners 'have not satisfied the stringent requirements for a stay pending court review'[1]. The ruling leaves the April 28, 2026 order in effect and does not resolve the consolidated challenges, which remain pending before the same court[1][2].
Undisputed Facts
- Two DEA final orders published in the Federal Register on April 28, 2026 moved marijuana in FDA-approved drug products, and marijuana subject to a qualifying state medical marijuana license, from Schedule I to Schedule III[6][7].
- Todd Blanche announced the action on April 23, 2026 while serving as Acting Attorney General, and signed the orders on behalf of DEA[9][27].
- Recreational, adult-use marijuana remains in Schedule I under federal law[9].
- Trump issued an executive order on December 18, 2025 directing the Attorney General to speed up the rescheduling process already underway[14].
- DEA held a separate administrative hearing on broader rescheduling that began June 29, 2026 and concluded July 15, 2026; participants were invited to file post-hearing briefs, and no recommendation has been issued[15][16].
- DEA selected seven participants for that hearing, all opposed to rescheduling, and did not select pro-rescheduling groups including NORML, which asked DEA in writing to reconsider[14].
- The Justice Department argued in its opposition brief that NDASA identified no concrete harm to an individual member and that MMJ cannot claim competitor standing because it has no authorized product on the market[4][5].
- The September 9 panel order denied the stay without resolving the merits of the consolidated petitions[1][2].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- A stay is a hard motion to win
- Courts grant stays only when a challenger shows a strong likelihood of winning, irreparable harm, and a balance of equities in its favor. The panel used the phrase 'stringent requirements'[1]. So the denial tells you the challengers fell short on that demanding test right now. It does not tell you the court thinks the order is lawful[2].
- Standing is the government's cheapest win
- If the court agrees the challengers lack Article III standing, it never has to decide whether DEA could skip notice and comment[4]. That is why DOJ led with who may sue, not with why the order is sound[5]. It is also why the challengers called standing a 'diversion'[4].
- Money moves before law settles
- Section 280E stops applying the moment a substance sits in Schedule III, so the covered medical category's tax position changed in April, not after final judgment[17]. Treasury and the IRS have already opened a guidance process[19]. Every month of that creates reliance that a later adverse ruling would have to unwind.
- Who is in the room shapes the record
- DEA seated seven participants in its broader hearing, all opposed to rescheduling, and excluded NORML and other pro-rescheduling groups[14]. Whatever the administrative law judge recommends will rest on evidence and cross-examination assembled mostly by one side. That is a structural fact about the record, separate from whether the recommendation is right.
- The treaty is a real constraint, not a talking point
- The 1961 UN Single Convention on Narcotic Drugs is the reason the April order is limited to FDA-approved products and state-licensed medical marijuana rather than covering marijuana generally[3][6][7]. DEA published a note defending its reading[24], and senators including Romney, Risch and Ricketts had pressed the agency on it[23]. The same treaty is one of the challengers' central weapons.
Material realityTwo narrow categories of marijuana are federally Schedule III today, and they have been since April 28, 2026[6][7]. Recreational marijuana is Schedule I[9]. That split is the concrete fact. It means state-licensed medical operators can now deduct ordinary business expenses, because Section 280E does not reach Schedule III[17]. Adult-use operators still cannot, and in several states that tax burden exceeds their entire net profit. Banking has not been solved: as long as marijuana is controlled at any level, banks, payment processors and insurers still carry federal exposure, so Schedule III alone does not open the financial system. Research restrictions did loosen in a specific way — Schedule III substances may be made, distributed and dispensed by holders of a valid DEA registration, which Schedule I forbids outright[18]. Meanwhile the DEA hearing on broader rescheduling closed July 15, 2026 with no recommendation yet, and later stages could run into late 2026 or 2027[15][16]. Whatever the D.C. Circuit eventually decides, the agency track and the court track are running at the same time, and either could change the picture.
Narrative as a weaponThree groups are working the frame. The Justice Department wants you to see a careful, research-driven half-step that keeps recreational marijuana illegal, and to see the plaintiffs as businesses defending revenue — hence 'pocketbook interests'[5][8]. The challengers want you to see an agency that made a big change by order and skipped the public comment step where inconvenient evidence gets filed, and to treat the 1961 treaty as a limit the government exceeded[3]. Congressional and social-conservative opponents want you to see a safety signal sent to the public before the science was in, and they have the clean fact that the state-license category never passed FDA review[12][25]. Reform groups and the industry want you to see a first step, and they point to a hearing whose seven selected participants all opposed rescheduling[14]. Two things get lost in nearly all of it. The order is far narrower than 'marijuana rescheduling' implies. And a denied stay is a ruling about what happens while the case is pending, not about who wins it[1][2]. Also worth noting: no overseas or non-Western coverage of this ruling turned up, so international reaction here is a gap in the reporting rather than a verified absence of interest.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asThe government says this is cautious, research-first policy, not legalization. Blanche said the change 'will enable more targeted, rigorous research into marijuana's safety and efficacy, expanding patients' access to treatments and empowering doctors to make better-informed health care decisions'[9]. The mechanism matters here. Schedule I substances cannot legally be made, sold or dispensed in the U.S. at all, and research on them faces heavy restrictions. Schedule III substances can be made, distributed and dispensed by anyone holding a valid DEA registration[18]. So DOJ's argument is that Schedule I was blocking the very studies critics demand before loosening anything. DOJ also says the order was deliberately narrow, keeping recreational marijuana in Schedule I and 'maintaining strict federal controls'[8]. On the lawsuit, DOJ's position is about who gets to sue: it told the court the challengers have 'pocketbook interests' in prohibition that do not 'systemically align' with the American public, and that speculation about how employers might behave is not the concrete injury Article III requires[4][5].
WhyDeliver on a presidential directive issued in December 2025 while keeping the legal ground defensible[14]. A narrow, treaty-anchored order is harder to strike down than a blanket one[3][24]. Winning on standing lets the government defend the policy without the court reaching the notice-and-comment question at all[4].
Impact on themThe stay denial keeps the administration's signature drug-policy move operating while the case runs[1]. Treasury and the IRS have already announced a process for tax guidance following the order, so agencies are building on it[19]. A later loss on the merits would unwind work already underway.
Frames it asNDASA's strongest case is practical, not moral. It represents companies and professionals who run workplace drug tests[3]. Its argument: once federal law recognizes a lawful medical category, a positive THC result stops being a simple yes-or-no. A medical review officer then has to work out whether the positive came from federally recognized medical use or from prohibited use[3]. NDASA says that extra review costs money, that some employers will simply drop marijuana testing rather than pay for it, and that companies will have to rewrite their policies[3]. Alongside MMJ, NDASA also makes a process argument: DEA was required to put the change out for public notice and comment before it took effect, and did not[3]. Notice-and-comment is the normal path — the agency publishes a proposal, the public files objections and data, and the agency must answer them. Skipping it, the challengers say, is how an agency avoids being confronted with evidence it would rather not address.
WhyProtect a testing market whose volume depends on marijuana being off-limits. DOJ named this directly, calling it a pocketbook interest[5]. NDASA's answer is that having a commercial stake does not make the injury imaginary — the added review work is the injury.
Impact on themIf the order stands, members face more ambiguous results and more medical-review labor, and possibly fewer employer clients running marijuana panels[3]. The stay denial means those changes proceed now rather than after a ruling.
Frames it asMMJ develops cannabis-based drugs meant to go through full FDA approval[3]. Its argument is about fairness between two paths. One path is the expensive, years-long clinical-trial route. The other is a state medical license. MMJ's position is that the April order hands the second path the same Schedule III status as the first, which devalues the investment that FDA review demands. It joins NDASA on the notice-and-comment claim and on the treaty claim — that the order goes beyond what the 1961 UN Single Convention on Narcotic Drugs permits[3]. That treaty commits signatories to keep specific controls on cannabis; the challengers read it as a ceiling on how far the U.S. can loosen by executive order. DEA has published its own note arguing the treaty leaves room for this step[24].
WhyPreserve the commercial advantage that FDA approval is supposed to confer. Challengers also called DOJ's standing arguments 'meritless diversions from its indefensible position on the merits,' signaling they want the court on the process question, not the plaintiff question[4].
Impact on themDOJ argued MMJ cannot show competitor injury because it has not yet brought an authorized product to market[4]. That gap is both its litigation weakness and its business reality.
Frames it asThis group's case is about signal and evidence. On December 18, 2025 — the same day Trump signed the executive order directing the Attorney General to expedite rescheduling — Rep. Pete Sessions and House Freedom Caucus chair Andy Harris led 26 Republicans in writing to President Trump: 'We write to urge you to oppose rescheduling marijuana, a harmful drug that is worsening our nation's addiction crisis'[11][25]. That letter predates the April 2026 order itself and the September stay fight by months, so it reflects the party's standing position rather than a fresh reaction to the ruling. CatholicVote's Kelsey Reinhardt told Fox News Digital that rescheduling 'would falsely signal that it's safe and medically proven, when it hasn't gone through FDA approval or long-term safety studies'[12]. That is a real tension in the policy: the state-license category by definition covers products that never went through FDA review. Former drug czar Bill Bennett and former HUD Secretary Ben Carson have both urged caution, Carson in a Fox News op-ed[11]. A separate Senate letter from Mitt Romney, Jim Risch and Pete Ricketts pressed DEA on treaty compliance[23].
WhyHold a Republican administration to a drug-policy position much of the party's base has long held, and keep pressure on before DEA acts on the broader hearing record[15][16].
Impact on themThey lost nothing directly on September 9 — the stay motion was not theirs. Their leverage now sits with the pending DEA proceeding and with midterm politics, where cannabis has become an issue in both parties[21].
Frames it asReform groups treat Schedule III as a first step, not the destination[9]. Their strongest concrete point is tax. Internal Revenue Code Section 280E bars businesses trafficking in Schedule I or II substances from deducting ordinary business expenses — rent, payroll, marketing — so a cannabis company can owe tax on revenue it never kept. In several states, that burden has exceeded adult-use operators' entire net profit. Section 280E does not apply to Schedule III, IV or V, so the covered medical category can now deduct like a normal business[17]. Treasury and the IRS have announced how tax guidance will follow[19]. Reform advocates also press a process complaint of their own: DEA's broader hearing seated seven participants, all opposed to rescheduling, and left out NORML and other pro-rescheduling groups, so the record being built is one-sided[14]. Groups that filed supportive comments include the American Nurses Association, the American Pharmacists Association and the Epilepsy Foundation[14].
WhyLock in the tax and research gains, then push toward full descheduling. Every month the order survives builds reliance interests that are harder to unwind.
Impact on themThe stay denial protects the tax relief for now[17][19]. Banking is a different story: lenders and payment processors still face federal exposure as long as marijuana is controlled at all, so Schedule III does not fix access to financial services by itself. Adult-use operators, still in Schedule I, get no 280E relief.
Like this article?
The Bias Ledger average rating 4
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| CNBC | U.S. center, business press | 2 | 'Marijuana reform is emerging as a midterm elections issue on both sides of the aisle' — treats the policy mainly as electoral and market news. | The frame is investor and campaign impact, which quietly sidelines the legal question of whether the order was lawfully issued. Explicitly bipartisan framing keeps it from tilting either way. |
| Cannabis Business Times | U.S. cannabis trade press, industry-funded | 3 | 'Federal Court Denies Anti-Rescheduling Parties' Motion to Stay Schedule III Cannabis Order' — accurate and procedural, with both sides' filings summarized. | The standing label 'anti-rescheduling parties' adopts DOJ's framing of the challengers as an interest bloc rather than naming them by function. Its earlier headline amplified DOJ's 'systemically align' line as the news hook[4]. Reporting on the filings themselves is close to the record. |
| The Marijuana Herald | U.S. cannabis-reform trade outlet | 3 | 'U.S. Court of Appeals Rejects Bid to Block Marijuana Rescheduling Order, Keeping Covered Marijuana in Schedule III' — quotes the panel's language and, notably, says 'covered marijuana.' | 'Rejects a bid to block' reads as a win for reform, though a stay denial is a threshold ruling. Against that, this headline is one of the few that flags the order's limited scope with the word 'covered' — a precision most coverage drops. |
| Forbes | U.S. center-right business press | 3 | 'DEA Kicks Off Historic Hearing On Cannabis Rescheduling Proposal' — event coverage of the June 29 hearing, framed as a milestone. | 'Historic' is the editorial word. It imports significance the hearing has not yet earned, since no recommendation has been issued[16]. |
| Fox News | U.S. right | 5 | 'House Republicans urge Trump against reclassifying marijuana as less dangerous drug' — coverage built around GOP and social-conservative pushback on the policy, with little on the September 9 procedural ruling. | Sourcing weight. Opponents are quoted at length and in their own framing; DOJ's research rationale appears briefly. The pieces do not explain that the order covers only two narrow categories and leaves recreational marijuana in Schedule I, which is the fact that most limits the 'signals it's safe' argument. |
| Marijuana Moment | U.S. cannabis-reform advocacy journalism | 5 | 'DOJ Marijuana Lawsuit Filing Cites Drug Testing Industry And Pharma Company "Pocketbook Interests" In Opposing Rescheduling' — leads with the government's most damaging characterization of the challengers. | Choosing DOJ's pejorative as the headline frames the challengers' motive before their argument is stated. The filing details it reports are specific and checkable; the ordering is the advocacy. |
| The Hill (Opinion) | U.S. center-right opinion page | 7 | 'Rescheduling marijuana would put politics ahead of science' — frames the move as political rather than evidence-driven. | Labeled opinion, so the slant is disclosed. The construction still assumes the conclusion in the headline, and does not engage the government's counter-mechanism — that Schedule I status is itself what limits the research the piece calls for[18]. |
References
- U.S. Court of Appeals Rejects Bid to Block Marijuana Rescheduling Order, Keeping Covered Marijuana in Schedule III — The Marijuana Herald · U.S. cannabis-reform trade outlet, pro-legalization editorial stance
- Federal Court Denies Anti-Rescheduling Parties' Motion to Stay Schedule III Cannabis Order — Cannabis Business Times · U.S. cannabis industry trade press, advertiser-funded by the sector it covers
- Anti-Rescheduling Parties Ask Court to Stay Schedule III Cannabis Order — Cannabis Business Times · U.S. cannabis industry trade press
- Cannabis Prohibition Interests Don't 'Systemically Align' With American Public, DOJ Says — Cannabis Business Times · U.S. cannabis industry trade press
- DOJ Marijuana Lawsuit Filing Cites Drug Testing Industry And Pharma Company 'Pocketbook Interests' In Opposing Rescheduling — Marijuana Moment · U.S. cannabis-reform advocacy journalism, reader- and sponsor-funded
- Schedules of Controlled Substances: Rescheduling of Marijuana (2026-08177) — Federal Register · U.S. government primary source
- Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III (2026-08176) — Federal Register · U.S. government primary source
- Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III — U.S. Department of Justice · U.S. government primary source; party to the litigation
- DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set to Consider Broader Rescheduling — Gibson Dunn · Corporate law firm client alert; represents regulated-industry clients
- Department of Justice Eases Control of Medical Marijuana (LSB11424) — Congressional Research Service · Nonpartisan congressional research arm; drafted for members of both parties
- House Republicans urge Trump against reclassifying marijuana as less dangerous drug — Fox News · U.S. right
- CatholicVote launches new campaign urging Trump to reject marijuana rescheduling plans — Fox News · U.S. right
- Rescheduling marijuana would put politics ahead of science — The Hill (Opinion) · U.S. center-right opinion contribution; labeled opinion by the outlet
- Federal Marijuana Rescheduling: Process and Impact — Drug Enforcement and Policy Center, Ohio State Moritz College of Law · University research center; academic, generally favors evidence-based reform
- DEA Hearing on Proposed Marijuana Rescheduling Begins June 29 — U.S. Drug Enforcement Administration · U.S. government primary source
- Cannabis Rescheduling: Next Steps After DEA Hearing — Recovered · Addiction-treatment referral site; commercial interest in treatment services
- What is 280E? — Marijuana Policy Project · U.S. pro-legalization advocacy organization
- Legal Consequences of Rescheduling Marijuana (LSB11105) — Congressional Research Service · Nonpartisan congressional research arm
- Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling — U.S. Department of the Treasury · U.S. government primary source
- Medical Marijuana Schedule III Litigation: The D.C. Circuit's First Major Test — Harris Sliwoski · Law firm blog representing cannabis-industry clients
- Marijuana reform is emerging as a midterm elections issue on both sides of the aisle — CNBC · U.S. center, business press
- DEA Kicks Off Historic Hearing On Cannabis Rescheduling Proposal — Forbes · U.S. center-right business press; contributor model
- Risch, Romney, Ricketts send letter to DEA highlighting concerns with rescheduling marijuana and compliance with US treaty obligations — U.S. Senate Committee on Foreign Relations · Republican committee majority press release; primary source for the senators' position
- Preliminary Note Regarding Treaty Considerations — U.S. Drug Enforcement Administration, Diversion Control Division · U.S. government primary source; agency defending its own authority
- Letter to President Trump Urging Him to Reject Marijuana Rescheduling (Dec. 18, 2025) — Office of Rep. Pete Sessions, U.S. House of Representatives · Republican member office; primary source for the signatories' position
- DOJ Head Sidesteps Questions on Schedule III Order, Adult-Use Cannabis — Cannabis Business Times · U.S. cannabis industry trade press
- Todd Blanche orders federal reclassification of medical marijuana as less dangerous — Colorado Politics · U.S. state-focused political outlet, center-right ownership (Clarity Media)